HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis (original) (raw)

Abstract

Liver steatosis is a main histopathological feature of Hepatitis C (HCV) infection because of genotype 3. Steatosis and/or mechanisms underlying steatogenesis can contribute to hepatocarcinogenesis. The aim of this retrospective study was to assess the impact of infection with HCV genotype 3 on hepatocellular carcinoma (HCC) occurrence in patients with ongoing HCV cirrhosis. Three hundred and fifty-three consecutive patients (193 men, mean age 58 ± 13 years), with histologically proven HCV cirrhosis and persistent viral replication prospectively followed and screened for HCC between 1994 and 2007. Log-rank test and Cox model were used to compare the actuarial incidence of HCC between genotype subgroups. The patients infected with a genotype 3 (n = 25) as compared with those infected with other genotypes (n = 328) had a lower prothrombin activity [78 (interquartile range 60-85) vs 84 (71-195) %, P = 0.03] and higher rate of alcohol abuse (48% vs 29%, P = 0.046). During a median follow-up of 5.54 years [2.9-8.6], 11/25 patients (44%) and 87/328 patients (26%) with a genotype 3 and non-3 genotype, respectively, develop a HCC. HCC incidences were significantly different among the genotype subgroups (P = 0.001). The 5-year occurrence rate of HCC was 34% (95% CI, 1.3-6.3) and 17% (95% CI, 5.7-9.2) in genotype 3 and non-3 genotype groups, respectively (P = 0.002). In multivariate analysis, infection with a genotype 3 was independently associated with an increased risk of HCC occurrence [hazard ratio 3.54 (95% CI, 1.84-6.81), P = 0.0002], even after adjustment for prothrombin activity and alcohol abuse [3.58 (1.80-7.13); P = 0.003]. For patients with HCV cirrhosis and ongoing infection, infection with genotype 3 is independently associated with an increased risk of HCC development.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (32)

  1. Piodi A, Chouteau P, Lerat H, He ´zode C, Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and rela- tionship with steatosis. Hepatology 2008; 48: 16-27.
  2. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cyto- pathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-115.
  3. Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM. Specific polymor- phisms in hepatitis C virus genotype 3 core protein associated with intracel- lular lipid accumulation. J Infect Dis 2008; 197: 283-291.
  4. Caste ´ra L, He ´zode C, Roudot-Thora- val F et al. Effect of antiviral treat- ment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53: 420-424.
  5. Mirandola S, Realdon S, Iqbal J et al. Liver microsomal triglyceride trans- Ó 2011 Blackwell Publishing Ltd HCV genotype 3 and HCC e521 fer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-1669.
  6. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46: 999- 1008.
  7. Jackel-Cram C, Qiao L, Xiang Z et al. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3- kinase-Akt-2 pathway. J Gen Virol 2010; 91: 1388-1395.
  8. Moriya K, Nakagawa K, Santa T et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepato- carcinogenesis. Cancer Res 2001; 61: 4365-4370.
  9. Paradis V, Mathurin P, Kollinger M et al. In situ detection of lipid perox- idation in chronic hepatitis C: corre- lation with pathological features. J Clin Pathol 1997; 50: 401-406.
  10. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity- related hepatic steatosis a premalig- nant condition? Cancer Res 2001; 61: 5016-5023.
  11. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-1067.
  12. Lerat H, Honda M, Beard MR et al. Steatosis and liver cancer in trans- genic mice expressing the structural and nonstructural proteins of hepa- titis C virus. Gastroenterology 2002; 122: 352-365.
  13. Wang AG, Lee DS, Moon HB et al. Non-structural 5A protein of hepa- titis C virus induces a range of liver pathology in transgenic mice. J Pathol 2009; 219: 253-262.
  14. Na TY, Shin YK, Roh KJ et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepa- titis B virus-associated hepatocellular carcinoma. Hepatology 2009; 49: 1122-1131.
  15. Grando-Lemaire V, Guettier C, Chevret S, Beaugrand M, Trinchet JC. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe dÕEtude et de Traitement du Carcinome He ´patocellulaire. J Hepatol 1999; 31: 508-513.
  16. Paradis V, Zalinski S, Chelbi E et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859.
  17. Bochud PY, Cai T, Overbeck K et al. Genotype 3 is associated with accel- erated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655- 666.
  18. McMahon BJ, Bruden D, Bruce MG et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastro- enterology 2010; 138: 922-931.
  19. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocel- lular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
  20. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk fac- tors. Gastroenterology 2004; 127: S35-S50.
  21. Payan C, Roudot-Thoraval F, Mar- cellin P et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: the GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 405-413.
  22. Cardoso AC, Moucari R, Figueiredo- Mendes C et al. Impact of peginter- feron and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
  23. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma develop- ment: a meta-analysis. J Hepatol 2009; 50: 1142-1154.
  24. Veldt BJ, Chen W, Heathcote EJ et al. Increased risk of hepatocellular car- cinoma among patients with hepati- tis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862.
  25. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hep- atology 2007; 45: 579-587.
  26. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is asso- ciated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-2496.
  27. Ohata K, Hamasaki K, Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-3043.
  28. Lok AS, Everhart JE, Chung RT et al. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrho- sis (HALT-C) trial. Hepatology 2009; 49: 1828-1837.
  29. Chen CH, Lin ST, Kuo CL, Nien CK. Clinical significance of elevated alpha- fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 1423-1427.
  30. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modu- lating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007; 22: S108-S111.
  31. He ´zode C, Zafrani ES, Roudot-Tho- raval F et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134: 432- 439.
  32. Adinolfi LE, Gambardella M, Andre- ana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progres- sion of liver damage of chronic hep- atitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358- 1364.